![]() |
市场调查报告书
商品编码
1306528
冠状动脉支架的全球市场:规模,占有率,趋势(2023年~2029年):MedCore,各类型市场区隔(传统金属支架,药物释放型血管支架)Coronary Stent Market Size, Share, Trends Analysis | Global | 2023 - 2029 | MedCore | Segmented by: Type (Bare-Metal Stents, Drug-Eluting Stents) |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计到 2029 年,全球冠状动脉支架市场将大幅增长至超过 48 亿美元。波士顿科学公司、美敦力公司、雅培公司等已成为主要参与者,占据了冠状动脉支架全球大部分市场占有率。
本报告提供全球冠状动脉支架市场相关调查,提供市场概要,以及各市场区隔,各地区趋势,竞争情形等资讯。
The global market size of coronary stents is projected to witness significant growth, exceeding $4.8 billion by 2029. Boston Scientific, Medtronic, and Abbott emerged as the key players dominating the majority of the global coronary stents market share. This comprehensive market research encompasses an in-depth analysis of coronary stents companies across over 70 countries worldwide.
This study conducted by iData Research on the global coronary stents market includes an analysis of procedure volumes to enhance the accuracy of market sizing. The analysis provides detailed information on procedure volumes spanning a 10-year period and encompassing 70 countries. This comprehensive approach ensures a robust understanding of market dynamics and trends related to coronary stents.
The Asia Pacific region emerged as the largest market for coronary stents, demonstrating substantial growth in unit sales. The growth of the coronary stent market in this region is closely linked to the annual volume of percutaneous coronary intervention (PCI) procedures. Any significant changes in the PCI procedure volume directly impact the sales volume of coronary stents. Furthermore, the implementation of systemic healthcare reforms, improved access to healthcare, and rising disposable income in the Asia Pacific region are anticipated to have a positive impact on the market for coronary stents. These factors collectively contribute to the growth and potential of the market in the region.
The global market size for coronary stents is projected to experience growth throughout the forecast period. The average selling price (ASP) within the coronary stent market is primarily influenced by the dominant drug-eluting stent (DES) segment, which constitutes a significant portion of the total units sold. Over the years, prices of DESs have substantially decreased since their initial introduction in 2003. This decline in prices can be attributed to factors such as unfavorable reimbursement conditions and intense competition within the market. However, moving forward, prices in the coronary stent market are expected to show growth. This increase in prices is driven by the prevailing trend of market consolidation. As the market undergoes consolidation, companies may have more control over pricing strategies, which can contribute to a rise in prices.
In 2022, the global coronary stents market was dominated by three key competitors: Boston Scientific, Medtronic, and Abbott.
Boston Scientific emerged as the leading competitor in the global coronary stent market. The company's success can be largely attributed to its strong position in the drug-eluting stent (DES) market, where it held a significant market share. Boston Scientific offers several product lines, including the PREMIER™ and SYNERGY™ DES, as well as the REBEL™ bare-metal stent (BMS). Notably, the SYNERGY™ DES stands out as the first and only FDA-approved DES with an abluminal bioabsorbable polymer coating available in the U.S. market. The REBEL™ BMS, made of a platinum chromium alloy, is designed to reduce device usage, procedure times, and radiation exposure, providing additional benefits to physicians and patients.
Throughout this comprehensive research series, iData Research has meticulously covered more than 70 countries worldwide, providing in-depth analysis and insights. Each global region is available as a stand-alone report, allowing you to tailor the data to your specific needs.